GlassScriptPhysician profile
Peter Keorpes
NPI 1861622441
$9,728.06
in general payments reported to CMS, 2019-2025
28 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,276 · 2022: $1,613 · 2023: $2,523 · 2024: $2,391 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,472 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,472.35 |
| Education | $366.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.55 | 2021-2025 | |
| Pfizer INC. | $1,162.50 | 2021-2025 | |
| Lilly USA, LLC | $834.48 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $766.13 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $739.63 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $657.44 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $625.56 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $581.08 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $500.17 | 2021-2025 | |
| Ucb, INC. | $419.30 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $336.29 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $295.27 | 2023-2025 | Zoryve |
| Amgen INC. | $219.42 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $213.10 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $204.23 | 2022-2025 | Adbry, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $189.03 | 2021-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.50 | 2023 | Cyltezo |
| Strata Skin Sciences, INC. | $56.49 | 2022-2024 | Xtrac |
| Sandoz INC. | $56.37 | 2023 | Hyrimoz |
| Organon LLC | $53.03 | 2024-2025 | Vtama |
| Mayne Pharma Commercial LLC | $52.01 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $43.66 | 2023-2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.29 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Vyne Pharmaceuticals INC. | $37.95 | 2021 | |
| Fresenius Kabi USA, LLC | $26.45 | 2023 | |
| Epi Health, LLC | $22.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.21 | 2021 | |
| Journey Medical Corporation | $14.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Keorpes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.